ABSTRACT
OBJECTIVES: The use of thrombopoietin-receptor agonists (TPO-RAs) has increased as a second-line therapy in ITP, but the efficacy and safety of such drugs has not been evaluated in SLE-associated ITP. METHODS: This was a multicentre retrospective cohort study from 2009 to 2016. Participating centres (n = 11) were secondary- or tertiary-care hospitals belonging to the French national network for adult ITP. RESULTS: We included 18 patients with SLE-ITP treated with TPO-RAs; 10 (55%) had aPL, 5 (27%) showing definite APS. Except for one patient, all (94%) achieved response with TPO-RAs overall. After a median follow-up of 14.7 months with TPO-RAs, four arterial thrombosis events (including one catastrophic APS) occurred in four patients. Two venous thrombosis events occurred in a patient without APS or aPLs. CONCLUSION: Our results suggest that aPLs should be systematically screened before TPO-RA initiation in patients with SLE. With aPL positivity, alternative therapy should be discussed (if possible), especially in patients with definite APS or suboptimal adherence to anti-coagulation therapy.
Subject(s)
Antiphospholipid Syndrome/drug therapy , Benzoates/adverse effects , Hydrazines/adverse effects , Lupus Erythematosus, Systemic/drug therapy , Pyrazoles/adverse effects , Receptors, Thrombopoietin/antagonists & inhibitors , Recombinant Fusion Proteins/adverse effects , Thrombopoietin/adverse effects , Thrombosis/etiology , Adolescent , Adult , Aged , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/diagnosis , Benzoates/administration & dosage , Female , Follow-Up Studies , France/epidemiology , Humans , Hydrazines/administration & dosage , Incidence , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/diagnostic imaging , Male , Middle Aged , Prognosis , Pyrazoles/administration & dosage , Receptors, Fc/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Retrospective Studies , Thrombopoietin/administration & dosage , Thrombosis/chemically induced , Thrombosis/epidemiology , Young AdultSubject(s)
COVID-19 , Hematologic Neoplasms , Antibodies, Viral , Hematologic Neoplasms/therapy , Humans , RNA, Messenger , SARS-CoV-2 , Seroconversion , VaccinationABSTRACT
Since 2006, new treatments as targeted therapies (anti angiogenic and mTOR inhibitors) are prescribed in renal cell cancer. Toxicity of these treatments is well known by clinicians. Occurrence of these side effects has been associated with anti tumoral efficacy. High blood pressure, hypothyroïdie and hand foot syndrome were reported to be predictive of anti tumoral response. Fatigue and hyponatremia are still largely discussed. Moreover, non infectious pneumonia, which frequently occurs with mTOR inhibitors, is associated with clinical benefit. The main objective of treatment of advanced kidney cancer, specially renal cell cancer, is obtaining clinical benefit (stabilization and response) with a chronic evolution of the disease. This prolong exposure to drugs, according to their toxicity profile, often contributes to dose reduction, moreover interruption of treatment, potentially associated with a loss of control of disease. Thus, the adverse effects, described hereby, may be considered as « positive events ¼, predicting efficacy, and thus looked for Moreover, the sequential approach, with new drugs, emphasizes the need of defining the optimal sequence. Thus, because of the lack of molecular biomarkers to date, this predictives secondary effects may help for selecting the therapeutic strategy.